Measurement of impurities to support process development and manufacture of biopharmaceuticals by Oshinbolu, S et al.
1 
 
Measurement of impurities to support process 
development and manufacture of biopharmaceuticals 
Review for Trends in Analytical Chemistry special issue: Control of Impurities 
 
 




1 Dept of Biochemical Engineering, University College London, Bernard Katz Building, 
Gordon Street, London, WC1H 0AH, United Kingdom  
2 GlaxoSmithKline, Gunnels Wood Road, Stevenage, Herts, SG1 2NY, United Kingdom 
 
Corresponding Author: 
Prof. Daniel G. Bracewell, Dept of Biochemical Engineering, University College London, 
Bernard Katz Building, Gordon Street, London, WC1H 0AH, United Kingdom  






















The biopharmaceutical industry is a growing market relying on analytical methods to bring 
safe and efficacious drugs from conception to market. Analytical methods are required during 
the entire drug life cycle as it plays a vital role during decision making. Impurities influence 
product quality, stability and efficacy, so their levels need to be minimised. There are 
regulatory guidelines that set out principles for consideration in meeting product quality 
specifications. Analytical methods have limits in their sensitivity and accuracy of 
measurement, their sample throughput and/or range of detection. This highlights the need to 
have orthogonal assays that can confidently quantify critical impurities to the appropriate 
levels. In this review, we discuss three major analytically challenging critical quality attributes 
– two product related impurities (aggregates and incorrect glycosylation) and one process 
related impurity (host cell proteins) – and the analytical assays that are commonly used to 
measure their quantity and quality. 
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Abbreviations  
2D-PAGE - Two-dimensional polyacrylamide gel electrophoresis 
ADCC - antibody-depedent cell-mediated cytotoxicity  
AUC / SV-AUC – (Sedimentation velocity) analytical ultra-centrifugation 
BiP - Binding immunoglobulin protein 
CD - Circular dichroism 
CHO - Chinese hamster ovary 
CPP – Critical process parameter 
CQA - Critical quality attribute 
Cryo-EM - Electron cryo-microscopy 
DLS - Dynamic light scattering 
ELISA - Enzyme linked immunosorbent assay 
ER - Endoplasmic reticulum 
FDA - Food and Drug Administration 
HCCF - Harvested cell culture fluid 
HCP - Host cell protein 
ICH - International Council for Harmonisation 
IgG - Immunoglobulin G 
LC - Light chain (of an antibody) 
mAb - Monoclonal antibody 
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MS / MS-MS / LC-MS / HDX-MS - Mass spectrometry / Tandem mass spec / Liquid 
chromatography with mass spec / Hydrogen-deuterium exchange mass spec 
MFI - Micro-flow imaging 
NMR - Nuclear magnetic resonance 
NTA - Nanoparticle tracking analysis 
PLBL2 - Phospholipase B-Like 2 
ppm - parts per million 
PTM - Post-translational modifications 
QbD – Quality by design 
QC - Quality control 
SAXS - Small-angle X-ray scattering 
SEC - Size exclusion chromatography 
TEM - Transmission electron microscopy 
UPLC - Ultra performance liquid chromatography 





































Recombinant therapeutic antibodies are a major player in today’s pharmaceutical industry, with 
biopharmaceuticals representing 24% of the global drug market and antibody derived drugs 
reaching sales of $82 billion in 2016 [1]. Half of the top 10 best-selling drugs are monoclonal 
antibodies (mAbs) [1] and they are mostly used to treat cancer and autoimmune diseases. Some 
recombinant therapeutics require post-translational modifications (PTMs) such as 
glycosylation for clinical efficacy. Hence, mammalian host expression systems that can make 
these modifications (such as Chinese hamster ovary (CHO) cells) are typically used [2]. 
However, microbial expression systems (e.g. E.coli) are still the preferred choice for biological 
medicines such as insulin that don’t require PTMs [2].  
 
In order to have a full understanding of the molecule being produced, analytical methods are 
required from discovery and process development through to clinical trials. As such analytics 
play a vital role in taking recombinant therapeutics from bench-to-market as it underlies all 
decision making. To achieve consistency in production, quality by design (QbD) is becoming 
a globally accepted strategy within the industry with the goal of enhancing pharmaceutical 
manufacture through design and control of processes [3]. The strategy systematically 
establishes critical quality attributes (CQA) of a drug product and critical process parameters 
(CPP) which are parameters with significant impact to CQAs [4]. CPPs and CQAs are used to 
create a design space in order to develop a control strategy. Three CQAs that have proven to 
be particularly challenging to monitor and control are aggregated product, incorrectly 
glycosylated product and host cell proteins. In this review, we will therefore discuss the 
importance of analytical assays and how regulatory guidelines aid to control these three CQAs. 
2 Regulatory guidelines  
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals 
for Human Use (ICH) publishes scientific guidelines that are harmonised between the 
regulatory authorities and the pharmaceutical industries in Europe, Japan and the United States 
of America. The ICH Q6B guideline sets out the principles for consideration in setting product 
quality specifications (appearance, identity, purity and impurities, potency and quantity) as 
well as appropriate analytical procedures. Similar guidelines on the quality, safety, and efficacy 
of biotherapeutic protein products prepared by recombinant DNA technology are provided by 
the World Health Organization [5]. These guidelines help to ensure the commercialisation of 
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only consistent, effective, high quality products that undergo a highly-regulated development 
process. To ensure these standards are being met, an extensive analytical toolbox is required, 
to enable the use of a wide range of analytical techniques that target different physicochemical 
properties of the product [5]. The assays and instruments are expected to be precise, 
reproducible, robust, and commonly orthogonal techniques are carried out to complement and 
provide confidence in results. Fast analytical methods that can produce large amount of data 
have become vital to speed up time-lines and the decision-making process. 
 
For efficient quality control, critical quality attributes (CQAs) are identified and closely 
monitored. A CQA as outlined in ICH Q8 (R2) is a “physical, chemical, biological or 
microbiological property or characteristic that should be within an appropriate limit, range, or 
distribution to ensure the desired product quality” [6]. Figure 1 outlines the key steps towards 
controlling CQAs, which can be product or process related. Product related impurities are 
molecular variants of the product such as aggregates, fragments, incorrectly glycosylated 
antibody or charge variants, whereas process related impurities are an inherent part of the 
process such as the host cells’ DNA or host cell proteins (HCPs), leachables (such as protein 
A) and viruses. The presence of these impurities in the final drug product can affect product 
purity, product efficacy and stability, and can cause adverse immune responses in patients such 
as anaphylaxis [7]. To ensure patient safety, impurities need to be reduced to acceptably low 
levels to meet the defined acceptance criteria. For mAbs, the final product should typically 
have <5% high molecular weight aggregates, <100 ppm HCPs and <10ng/dose DNA [8, 9], 
although in reality aggregation and HCP limits are case-by-case dependent and are defined 
from (pre-)clinical studies and manufacturing consistency lots [10]. 
3 Analytics during the drug lifecycle 
Analytical methods are essential from drug discovery through to clinical trials, and even after 
regulatory approval. They are needed to ensure full characterisation of the molecule, however 
the extent of analytics used differs throughout the product lifecycle. At the earlier stages of the 
lifecycle (drug discovery and development) detailed characterisation is required to understand 
the product and how different process conditions change the product profile, so that we can 
define the manufacturing strategy. Comparability studies as addressed in the ICH Q5E 
guideline might also be required. By contrast, once the manufacturing process is defined and 
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controlled, it might not be necessary to perform extensive quality control (QC) at later stages. 
In particular, for manufacturing lots that are released for clinical studies, it may be acceptable 
to select only a subset of appropriate assays, since the production process should be tightly 
controlled and consistent at this stage [10].  
 
It should be noted that single assays do not always provide a true representation of a molecule. 
Biopharmaceuticals are complex molecules which are constantly moving in solution. Some 
analytical techniques allow protein samples to be measured in the native state while others 
measure proteins in a non-native state conformation. In this sense, some analytical methods 
can be destructive, meaning either that sample treatment irreversibly denatures the protein, 
preventing the sample to be reused for other means, or that the sample is consumed during the 
measurement. Non-destructive methods are typically preferred as this allows a single sample 
to be reused for other analytical methods. 
 
Figure 2 shows a typical bioprocess flow diagram for the production and purification of 
biopharmaceuticals (upstream and downstream processing respectively) and highlights the key 
stages at which assays are required to demonstrate efficient impurity clearance. Advances in 
the measurement of three typical CQAs of importance that will be discussed in this review are 
aggregation, glycosylation and HCPs. Aggregates can form during the protein synthesis as well 
as during product purification while on the chromatography column, and therefore need to be 
tightly controlled. Incorrect glycosylation of proteins can severely affect efficacy and stability 
of the drug substance, and HCPs can likewise affect the product stability, but more importantly 
could pose severe immunological risks to the patients if not reduced to acceptably low levels. 
Since these three CQAs have proven to be particularly challenging to monitor and remove from 
the final drug product, we will focus on them in this review, although it should be noted that 
there are many more potential CQAs.  
4 Aggregation 
Aggregation is the self-association of protein molecules and can differ in morphology, 
solubility, structure, reversibility and intermolecular bonding. Moussa et al. [11] reviewed the 
issues of aggregated therapeutic proteins causing adverse immune responses in patients. The 
adverse immune response can cause problems for both patient safety and product efficacy [7]. 
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Therefore, in order to ensure patient safety, it is important to improve our understanding of 
protein aggregates and use the most appropriate analytical techniques to monitor aggregate 
content. Molecular weight, structure and solubility are the three main features used to 
characterise aggregates. As there are different sizes and different mechanisms of aggregation, 
aggregates can be difficult to characterise with one single technique. Figure 3A summaries the 
key advantages of the different techniques used for measuring aggregates. 
4.1 Analytics for aggregation quantification and sizing 
Size exclusion chromatography (SEC) is the most common technique to quantify and size 
soluble aggregates less than 50 nm (Figure 3B). It is the most typically used technique of 
ensuring that the amount of mAb aggregates meet regulatory guidelines (<5%). It is a robust 
and well-established technique with separation on the column occurring based on size. Larger 
molecules which have less accessibility to the pores elute first. SEC combined with multi-angle 
light scattering (MALLS) can provide conformation of the average molecular weight of 
species. SEC-MALLS is also more sensitive to higher order aggregates which may not be 
detected by SEC alone [12]. SEC is not suited to analyse insoluble or large aggregates as they 
often get trapped by frits which protect the column. Additionally, the mobile phase dilutes 
samples from initial loading concentration, which can cause weakly associated aggregates to 
dissociate. Therefore, it is important to bear in mind when analysing results that SEC may not 
be a true representation of a sample. Asymmetrical Flow Field Fraction (AF4) is an alternative 
analytical technique which can quantify larger aggregates than SEC (even insoluble 
aggregates). However, it is not as mature as SEC and requires in-depth method 
development[13]. 
 
Dynamic light scattering (DLS) is commonly used in industry to estimate the size and relative 
percentage of aggregate species. The scattering of light depends on the molecular weight, 
concentration and shape of the molecule, as well as the light/laser wavelength and scattering 
angle [14]. DLS is more capable of measuring larger aggregates across a wider sample 
concentration range (0.1–50 mg/ml) than SEC [15]. As intensity of light is proportional to 
molecular weight, the technique is highly sensitive but often biased to large aggregates as they 
scatter light more strongly. The technique is poor at resolving small oligomers such as dimers 
and trimers as it requires a three to four fold [15] difference in hydrodynamic size to resolve 
different species. Techniques such as nanoparticle tracking analysis (NTA) and micro-flow 
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imaging (MFI) can characterise larger aggregates and particulates which are important to be 
aware of, especially when the molecule is in the final formulation. NTA is employed for sizing 
submicron particles (10 nm–1 µm) whereas MFI is for micro particles (1–100 µm) [16]. Both 
techniques enable sample visualisation, however NTA is less reproducbile and requires several 
optimisation steps by a skilled operator. NTA is also very sensitive to the buffer which can 
raise the interference from the background and make it difficult for the software to track 
aggregates. MFI requires large amounts of sample and high shear forces can cause particle 
fragmentation [17]. 
 
Sedimentation velocity analytical ultra-centrifugation (SV-AUC) uses high centrifugal speeds 
to study sedimentation behaviour. Radial separation causes larger species to sediment to greater 
extent than smaller molecules. AUC covers the intermediate size between SEC and DLS with 
excellent separation and detection for low level aggregates ≤1% [18]. Berkowitz [19] showed 
comparable dimer levels to SEC in samples with a range of dimer content. The major limitation 
with AUC is its low throughput, as it takes 12 hours to run a single sample. Samples are 
measured in the native state and although it is not completely destructive it is not recommended 
to use for other aggregation assays. Analysis of data is also time consuming and requires 
operators with expert experience. Although AUC is more expensive than SEC and DLS and 
requires regular calibration and intensive maintenance, it is commonly used to validate a SEC 
method. 
 
Overall, not a single technique can provide information on quantification and size estimation. 
Although SEC is a gold standard in the industry, both AUC and DLS serve as orthogonal 
techniques to SEC as they can detect aggregates not characterised by SEC and thus increase 
confidence in data interpretation. 
4.2 Analytics for structural analysis of aggregates 
Structural analysis can give insight into the mechanism of formation as well as the state of the 
protein (native or non-native). There are several techniques that can structurally characterise 
proteins [20] but for this review the following methods will be discussed: circular dichroism 
(CD), hydrogen-deuterium exchange mass spectrometry (HDX-MS), cross-linked mass 
spectrometry, small-angle x-ray scattering (SAXS), transmission electron microscopy (TEM) 
and electron cryo-microscopy (Cryo-EM) and fluorescence spectroscopy.  
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CD has become recognised as a valuable structural technique to provide information on 
secondary and tertiary structure. CD measures the difference between the absorption of left and 
right circularly polarised light [21]. Operating in the far-UV (180-260 nm) provides 
quantitative estimates on the secondary structure (e.g. percentage helix, turns and sheets), 
whereas operating in the near-UV (240-340 nm) regions provides quantitative estimates on 
tertiary structure conformation [14]. CD is easy to perform and offers speed and convenience 
in comparison to NMR and X-ray crystallography as it requires low sample concentration, does 
not require crystallised samples and samples can be recovered [22]. However, the technique 
provides low resolution and sensitivity for mAbs. Historically, CD has been primarily used to 
investigate the secondary structure (alpha helix, beta sheets, etc.) for small molecules/proteins.  
The technique appears to be more sensitive to changes in alpha helices than beta sheets. Large 
molecules such as mAbs are primarily comprised of many beta sheets. Therefore, CD lacks the 
sensitivity and resolution to measure small and specific secondary structural changes as the CD 
outputs are averaged out.  
 
For larger molecules, there are emerging complementary technologies which can provide 
greater resolution to understand structure related aggregation pathways. Cross-linked MS 
consists of covalently connecting two function groups of the protein(s) to gain insight into the 
three dimensional structure of proteins in solution using MS [23]. MS analysis can occur with 
the intact protein or after enzymatic digestion. HDX-MS can pinpoint structural changes down 
to the primary structure [24]. It probes the exchange kinetics of hydrogen for deuterium and 
has been able to elucidate the aggregation mechanism for mAb dimers [25]. SAXS and TEM 
can measure quaternary structure. SAXS can provide structural information on shape and size 
at 1-2 nm resolution [26] and TEM has been shown to visualise mAbs aggregated on the Fc or 
Fab region [27].  
 
Fluorescence spectroscopy is a highly sensitive technique for both structural characterisation 
and aggregation detection. Fluorescence can be measured intrinsically from naturally 
fluorescent amino acids (e.g. tryptophan) or extrinsically with the addition of dyes. The 
increased focus on measuring protein aggregation for therapeutic protein manufacturing and in 
disease states, has resulted in an increase in publications using dyes for protein characterisation. 
Measuring intrinsic vs. extrinsic fluorescence is often a trade-off between the intensity of 
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fluorescence signal and invasiveness [28]. Extrinsic fluorescence can be used to monitor 
protein folding/unfolding and detecting small amounts of large aggregates typically undetected 
by SEC [29].  
4.3 Aggregation in the process environment  
During the expression of recombinant therapeutics, aggregation can occur both intracellularly 
during synthesis as well as in the culture medium after secretion [30]. From an extracellular 
perspective, the exposure of the recombinant therapeutics to physical (e.g. agitation, aeration), 
chemical (e.g. pH) and biological damage (e.g. proteases) can cause conformational changes. 
From an intracellular perspective, recombinant cells express and fold higher amounts of 
proteins than they normally would. Under cellular stress and/or when high amounts of proteins 
are expressed, chaperones in the endoplasmic reticulum (ER) such as BiP can become 
overwhelmed. This can prevent proper folding of the nascent proteins in a timely and precise 
manner. Unfolding/misfolding results in the exposure of hydrophobic patches of the peptide 
structures which are prone to aggregation [30, 31]. Aggregates can also form during protein 
purification while on the chromatography column. This shows the impact that upstream and 
downstream conditions can have on the stability of the product, highlighting the importance of 
having process understanding of aggregation.  
5 Glycosylation 
Glycosylation is an important post-translational modification that occurs during protein 
expression in eukaryotic cells. It is the most complex post-translational modification in terms 
of chemical heterogeneity. Carbohydrate complexes termed glycans are added to proteins, 
through attachment to specific amino acids, and play a role in many functions such as solubility, 
stability, binding and efficacy. Glycosylation of recombinant therapeutics is dependent on the 
expression system and growth conditions; hence the upstream processing conditions directly 
impact correct glycosylation formation. Glycosylation pathways are influenced and dependent 
on cell culture conditions [32] as well as on cell engineering. Pande et al. [33] have shown how 
the addition of a small molecule ionophore can promote specific glycosylation pathways. For 
mAbs that rely on Fc-mediated effector function, changes in Fc glycans can affect the safety 
efficacy and mechanism of action [34]. One example is Reusch and Tejada [34] found evidence 
that afucosylated Fc glycans increase antibody-dependent cell-mediated cytotoxicity (ADCC). 
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Consequently, there has been a lot of development to measure and monitor glycosylation 
patterns. 
 
The ICH Q6B guideline states that “for glycoproteins, the carbohydrate content should be 
determined. In addition, the structure of the carbohydrate chains, the oligosaccharide pattern 
and glycosylation sites of the polypeptide chain should be analysed to the extent possible” [10]. 
The European Medicines Agency states that “glycan structure should be characterised and 
particular attention should be paid to their degree of mannosylation, galactosylation, 
fucosylation and sialylation. The distribution of main glycan structure present (often G0, G1 
and G2) should be determined” [35]. To determine this, there are three different approaches of 
measuring glycosylation: released glycan assay, glycopeptide and intact IgG mass 
spectrometry (MS) analysis. Zhang et al. [36] described the different analysis approaches for 
structural characterisation using mass spectrometry. For detailed structural analysis, the 
amount of sample preparation required is often a trade-off between sample complexity and 
information obtained. The longer the sample preparation time (decreasing throughput), the 
more structural information (e.g. sites and linkages) can be obtained.  
5.1  Releasing glycans 
Glycan analysis utilises enzymes or chemicals to release glycans to allow in-depth analysis of 
oligosaccharide structures, glycan profiling and quantify amounts of individual 
monosaccharides (such as mannose, galactose and fucose). There has been progress over the 
last few years to automate and increase the throughput for glycan analysis. Burnina et al. 
described a cost effective plate based sample preparation which denatures, reduces and 
deglycosylates 96 samples in 90 minutes compared to days [37]. Microfludic devices have been 
shown to integrate glycan cleavage, purification and chromatography separation and MS 
detection, reducing both time and amount of sample required [38]. Liquid handling systems 
have also been incorporated to create an automated sample preparation platform [39].  
 
While released glycan analysis is considered the gold standard for quantification, MS is the 
gold standard for qualitative characterisation of glycans. After chemical or enzymatic release, 
samples need to be purified which includes desalting and enrichment to isolate the protein of 
interest by chromatography, electrophoresis or covalent based interactions. Tandem MS (often 
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quoted as MS/MS) is an alternative approach to obtain glycan identification and sequencing 
using a multi-step MS that can provide purification and analysis in one system [40].  
5.2 Bottom-up and top-down approach 
A second approach utilises enzymes to release glycopeptides to determine and evaluate sites 
of attachment of glycopeptides and heterogeneity. This is often referred to as the bottom-up 
approach or peptide mapping. Although enzymatic cleavage increases sample complexity and 
interpretation difficulty, enzymes can be immobilised allowing re-usability, automation and 
reduced digestion time [41, 42].  Similar to glycan release, samples need to be purified before 
analysis. The third approach of analysis, the top-down approach, measures intact IgG. This 
allows quantitation of the main glycoforms (G0, G1 and G2) and deduction of the overall 
glycan composition. However, with intact IgG, small modifications or changes in the micro-
heterogeneity often have a too small effect to be resolved using analytical techniques.  
5.3 Analysis with mass spectrometry 
MS can be used to determine amino acid sequence, locate disulphide linkages, elucidate 
oligosaccharide profiles and identify other post-translational modifications [43]. It is a versatile 
technique for glycosylation analysis as it can characterise structural changes of intact 
glycopeptides and glycans. Ionisation variability, suppression and difficulties in resolving 
isoforms with small mass differences are the major limitations of the technique. For these 
reasons, it is often combined with chromatographic and electrophoretic techniques, to separate 
isoforms prior to MS analysis.  
6 Host Cell Proteins 
The host cells that are implemented for the expression of recombinant therapeutics produce not 
only the desired antibody but also indigenous proteins, known as host cell proteins (HCPs). 
They are present in the harvested cell culture fluid (HCCF) and are process related impurities 
requiring separation from the product. The composition of HCPs can vary with the process 
conditions under which the cells are grown [44]. HCPs also differ based on whether they are 
mammalian, bacterial or yeast-derived (e.g. Chinese Hamster Ovary, E.coli or Pichia pastoris 
respectively) [45]. HCPs are a complex mixture of a huge variety of proteins with significantly 
diverse physicochemical properties (e.g. pI, molecular weight and degree of hydrophobicity) 
[44, 45], which makes it necessary to use multiple techniques for efficient clearance. Shukla et 
al. [46] have investigated two strategies to demonstrate robust HCP clearance during 
13 
 
downstream purification steps. The reason why HCP removal is so essential is not only due to 
the possibility that they might influence the efficacy of the drug product, but also because they 
can cause adverse immune reactions in patients, including cross-reactivity and autoimmunity, 
and as such are a major safety concern [45, 47]. One notable case was published by Genentech 
about phase III clinical trials for the asthma drug Lebrikizumab. Material for this study was 
found to contain high amounts of the HCP species PLBL2 which caused a notable 
immunogenic response in ~90% of subjects, although no adverse safety effects were observed 
[48]. 
6.1 Analytics for HCP quantification and identification 
Enzyme-linked immunosorbent assays (ELISAs) are considered a gold standard for the 
quantification of HCPs, and are most commonly used to ensure the drug specification limits of 
HCP impurities are met. The antibodies used in such assays are produced by immunised 
animals such as goats or rabbits. Therefore, only HCPs with immunogenicity in the host 
animals will be accurately measured. For HCPs which do not cause an immune reaction in the 
immunized animals, there will be no specific antibody produced and so they will not be 
detected in the corresponding ELISA. As an ELISA is unlikely to detect 100% of HCPs, it is 
only semi-quantitative and does not provide absolute results about the total mass of HCPs 
present in a sample [9]. Moreover, this type of ELISA does not provide any information about 
the identity of the HCP species that are present. 
 
The identity of HCP species can be investigated by two-dimensional polyacrylamide gel 
electrophoresis (2D-PAGE) and liquid chromatography with tandem mass spectrometry (LC-
MS/MS). Electrophoresis with sensitive protein staining enables the visualization of the 
proteins, and 2D electrophoresis supplies information about the distribution of HCP species by 
molecular weight and isoelectric point. Coupled with LC-MS/MS, these species can be 
identified and quantified. This approach allows for HCP species with low immunogenicity to 
be recognized as well. However, low abundance proteins are often masked by highly abundant 
ones and are less likely to be identified [49]. This is a concern when trying to quantify and 
identify low abundance HCPs in the presence of highly abundant antibody product. To address 
this issue, recent advances in mass spectrometry have enabled improvements in the specificity 
and dynamic range using targeted mass spectrometry techniques, e.g. using a Q-Exactive mass 
spectrometer which contains a quadrupole mass filter and orbitrap mass analyser for high 
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resolution and accurate mass (HR/AM) measurements [50-52]. Recent research has 
demonstrated that it is possible to quantify HCPs down to single-digit ppm range within 1 hour 
for real time bioprocess development support [53]. However, it should be noted that MS-based 
HCP detection is limited by the software. If it’s not programmed to search for certain species, 
then these will not be detected.  
 
If a certain HCP species of interest needs to be identified, ELISAs using antibodies raised 
against a specific problematic HCP species can be carried out. Alternatively, western blots can 
be performed – again, either using a polyclonal mix of anti-HCP antibodies to verify the 
presence of HCPs in general, or using antibodies raised against a specific HCP species to 
identify the particular HCP species in question [49]. However, this approach is very time 
consuming and it can be expensive to raise antibodies against several specific types of HCPs. 
Additionally, only HCP species that are immunogenic and against which antibodies can be 
raised in the first place, will be able to be identified using this technique [49]. Table 1 
summarizes the advantages and disadvantages of each analytical assay, and often it may be 
necessary to use several orthogonal assays to ensure confident HCP detection and 
characterisation. 
6.2 Significant Research to Date 
6.2.1 HCPs co-elute with mAbs during protein A chromatography 
When it was first discovered that significant amounts of HCPs were not being efficiently 
separated during the antibody purification process, but were in fact retained during protein A 
affinity chromatography, it was unclear whether the host cell proteins co-eluted with antibodies 
by non-specifically binding to the resin or by associating with the bound antibodies. Nogal et 
al. [45] have sufficiently demonstrated that the latter was the case. They performed two protein 
A chromatography runs; in the first case, mAb free HCP material was loaded onto clean Protein 
A resin, whereas in the second case, the mAb free HCP material was loaded onto a Protein A 
column that already had antibodies bound to it. It was found that upon elution, the HCP levels 
were significantly higher in the second run, demonstrating that most HCPs species co-purify 
during protein A affinity chromatography due to their interactions with the bound antibodies.  
 
Nogal et al. [45] also demonstrated that only select subpopulations of host cell proteins co-
elute with the antibody during protein A affinity chromatography. They loaded harvested cell 
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culture fluid containing antibody and HCPs onto protein A resin, spiked the flow-through with 
purified antibody again and recycled this material for a total of five cycles. They noted that 
HCP levels in the flow-through samples remained fairly consistent while eluate samples from 
the five cycles contained rapidly decreasing levels of HCPs. They concluded that only specific 
subpopulations of HCPs co-elute with the antibody, which were gradually depleted from the 
load material. 
6.2.2 Identification of co-eluting HCP species 
Furthermore, considerable research has been done recently to identify the specific HCP species 
that are being retained during protein A affinity chromatography with certain antibodies. HCPs 
reported to be present include those that are involved in essential cell survival processes such 
as in translation (e.g. elongation factor 2), in protein folding (e.g. heat-shock proteins Hsp70 
and Hsp90 and clusterin), and in glucose or lipid metabolism (e.g. Glyceraldehyde 3-phosphate 
dehydrogenase, pyruvate kinase, lactate dehydrogenase; PLBL2) [48, 54-56]. In addition, 
proteases such as cathepsins and serine protease HTRA1 have been identified [54-56], 
particularly during late stages of the cell culture process when they are suggested to cause 
fragmentation [54, 57]. 
6.2.3 Effects of upstream process parameters on HCP composition 
Work has also been done to investigate whether certain upstream process conditions affect the 
composition of HCPs present in HCCF. For instance, Jin et al. [44] studied how media, 
temperature, feeding strategy, agitation speed, process duration and cell viability impact the 
levels of total HCPs. They found low cell viability to have the most significant effect on HCP 
composition. Not only did they measure higher levels of HCPs at day 15 – when viability was 
only 11% – but they also discovered that low molecular weight species were more abundant at 
this time in the fermentation process, suggesting the release of proteases and the associated 
degradation of proteins at low viability. This suggests that viability needs to be closely 
monitored, although it should be noted that the viability of 11% observed in this research is not 
a realistic manufacturing process viability. Tait et al. [55] have also reported that the changes 
in environment, metabolism and declining viability at the end of the fermentation period result 
in different compositions of HCPs at the end of the process compared to earlier days. Both the 
work from Jin et al. [44] and Tait et al. [55] suggest that the time of harvest is a crucial 
parameter with regards to HCP composition and that cell culture duration and cell viability 




The increasing number of biopharmaceuticals being brought to market require a versatile 
analytical toolbox to verify that only safe and efficacious drugs of high quality are 
commercialised. Analytical methods are required throughout the entire drug life cycle – from 
discovery and process development through to clinical trials and final market distribution – and 
therefore play a vital role in success. The approach to quality specifications throughout are 
governed by guidelines published by the ICH and are harmonised between the regulatory 
authorities and the pharmaceutical industries in Europe, Japan and the United States of 
America. In this review, we have discussed three major CQAs and the analytical methods that 
are most commonly used to measure their quantity and/or quality. Aggregates and HCPs are 
impurities that can severely affect product quality and therefore need to be reduced to 
acceptably low levels. Glycosylation is an important post-translational modification that needs 
to be carried out correctly by the cells. Different glycosylation patterns can influence the drug 
solubility, stability, binding and efficacy, hence the glycosylation profile needs to be 
controlled. The impacts these impurities can have, show the importance of having a defined set 
of analytical assays to quantify the impurities in a sensitive and consistent manner. When 
combined with process understanding of their origin, they allow those working in process 
development and manufacturing to be aware of all product quality issues that may have been 
caused by any process changes. Looking to the future, the ultimate goal would be for analytical 
methods to support the development and production of therapeutic proteins in real-time. While 
the development of online assays still provides difficulties, it is likely that we will see more at-
line assays coming to fruition in the future. 
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10 Figures and tables 
 
Figure 1 
Steps to controlling quality attributes. Schematic of the necessary steps/questions that need to 
be asked in order to ensure control quality attributes in a process. 
 
Figure 2 
Bioprocess flow diagram, showing the stages during upstream (green) and downstream (blue) 
processing along with components that are entered and removed from the process. 
 
Figure 3 
(A) Size-based detection ranges of various analytical techniques for aggregation. Data obtained 
from Sharma and Kalonia 2010; Engelsman et al. 2011. Size Exclusion Chromatography 
(SEC), Dynamic Light Scattering (DLS), Analytical Ultra centrifugation (AUC), Nanoparticle 
Tracking Analysis (NTA). 
(B) Summary of the different techniques for aggregate characterisation.  Data compiled from 
Sharma and Kalonia [14], Engelsman et al. [13], Kelly et al. [21], Corrêa and Ramos [58], Cole 
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Technique Advantages Disadvantages 
ELISA 
Highly sensitive & fast 
measurements of HCP amounts 
Only semi-quantitative and 
unable to identify HCP species 
2D-PAGE or 
2D-DIGE 
Visualises HCPs and provides 
information about molecular 
weight and isoelectronic point 
Abundant proteins mask less 
abundant ones and make 
detection of the latter impossible 
LS-MS/MS  
(coupled with 2D 
electrophoresis) 
Identifies HCP species of 
interest 
Takes a lot of time and work 
Western blotting 
Confirms presence of (specific) 
HCP species 
Only works on immunogenic 
HCPs for which antibodies are 
available; can be expensive 
 
Table 1 
Advantages and disadvantages of various analytical tools for the measurement of host cell 
protein and aggregate impurities. 
